657 related articles for article (PubMed ID: 26585985)
1. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
3. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
Iijima K; Sako M; Kamei K; Nozu K
Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
[TBL] [Abstract][Full Text] [Related]
5. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
[TBL] [Abstract][Full Text] [Related]
6. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
8. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Dötsch J; Müller-Wiefel DE; Kemper MJ
Pediatr Nephrol; 2008 Jan; 23(1):3-7. PubMed ID: 17899207
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
Smith GC
Pediatr Nephrol; 2007 Jun; 22(6):893-8. PubMed ID: 17310362
[TBL] [Abstract][Full Text] [Related]
11. Nephrotic syndrome and rituximab: facts and perspectives.
Haffner D; Fischer DC
Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for nephrotic syndrome in children.
Iijima K; Sako M; Nozu K
Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
[TBL] [Abstract][Full Text] [Related]
13. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G
Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
Basu B; Mahapatra TK; Mondal N
Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for childhood refractory nephrotic syndrome.
Iijima K
Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
Ravani P; Rossi R; Bonanni A; Quinn RR; Sica F; Bodria M; Pasini A; Montini G; Edefonti A; Belingheri M; De Giovanni D; Barbano G; Degl'Innocenti L; Scolari F; Murer L; Reiser J; Fornoni A; Ghiggeri GM
J Am Soc Nephrol; 2015 Sep; 26(9):2259-66. PubMed ID: 25592855
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
[TBL] [Abstract][Full Text] [Related]
19. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
Front Immunol; 2021; 12():726428. PubMed ID: 34621271
[TBL] [Abstract][Full Text] [Related]
20. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
Benz K; Dötsch J; Rascher W; Stachel D
Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
